The most important question in any emerging field of medicine is not whether the science works. It is whether the people who need it can actually access it.
Jaye Camposanto Andaya has made that question the organizing principle of her career. As a licensed Physician Associate with 18 years of clinical experience, a personal history with regenerative medicine, and a growing portfolio of ventures dedicated to responsible technology introduction, she is working to ensure that as regenerative medicine matures, it does so with the patient, not the market, at its center.
A Career Spent in Service of the Patient
Before Jaye Camposanto Andaya became an advocate for regenerative medicine, she spent nearly two decades learning what patients actually need from the people who care for them.
Her clinical background spans orthopedics, sports medicine, neurosurgery, general surgery, pain management, and urgent frontline care. These are environments that leave little room for abstraction. In each of them, the patient in front of her was the only variable that mattered. That orientation, patient-first, education-forward, outcomes-focused, became the lens through which she would eventually evaluate everything else, including the emerging technology that would change the course of her own life.
She was named to Marquis Who’s Who in America for 2024 to 2025, received a Top Doc designation from findatopdoc.com in 2023, and was named a P.O.W.E.R. Honoree, Professional Organization of Women of Excellence Recognized, for 2026. Each recognition reflects a career defined not by self-promotion but by sustained, credible service.
When She Became the Patient
The turning point in Jaye Camposanto Andaya’s journey from clinician to advocate was not a professional decision. It was a personal one, made from a hospital bed rather than a boardroom.
Navigating serious illness as a trained clinician is a disorienting experience. She understood her condition with a precision most patients are not afforded. She also understood, with equal clarity, the limits of what conventional medicine could offer her. It was in that space, between what she knew and what was available, that she encountered a category of cell-free nanotechnology developed in Japan. The results, documented publicly in a before-and-after video she has shared openly, were significant enough to reorient everything that followed.
The experience gave Jaye Camposanto Andaya something that clinical training alone cannot provide: the perspective of a patient who has been failed by the gaps in a system, found something that worked outside of it, and decided that the responsible thing to do with that knowledge was to make it available to others.
“Your most difficult season may be the one that most qualifies you,” she has said. Her advocacy work is the proof of that conviction in practice.
Building Access Where None Existed
The ventures Jaye Camposanto Andaya has built since her recovery are, at their core, access projects. Each one is designed to close a specific gap between a promising technology and the patients and practitioners who could benefit from it.
Pacific Biolúme Distribution Co., Inc. is the commercial infrastructure she founded to bring Japanese nanotechnology innovation to the U.S. aesthetics and wellness market, beginning in Hawaiʻi. The company is not simply a distribution channel. It is a deliberate effort to make a technology that is well established in Japan available to American consumers who have had no reliable path to it, paired with the education and clinical context needed to evaluate it honestly.
JCA Global Regenerative Advisory LLC operates at a different level of the same mission. As an advisory platform dedicated to bridging clinical credibility, cross-cultural relationship building, and ethical advocacy for emerging regenerative technologies, JCA Global works to build the reputational and educational infrastructure that responsible market introduction requires. It is, in her framing, the conversation that has to happen before the product can be trusted.
Her role as Global Ambassador and U.S. Clinical Liaison for Novatrail, Inc., the Japan-based biotech company behind the regenerative product line that anchors her distribution work, completes the picture. In that capacity, Jaye Camposanto Andaya supports clinical education and partnership development across the United States, ensuring that the technology reaches not just consumers but the clinicians who can evaluate and recommend it responsibly.
The Equity Dimension
What distinguishes Jaye Camposanto Andaya’s advocacy from conventional health entrepreneurship is the consistency with which she returns to questions of access and equity rather than simply market opportunity.
She speaks often about a world where regenerative medicine’s transformative potential is not gatekept by geography, culture, or a lack of access to credible information. That framing is not incidental. It reflects a conviction shaped by her own experience as a patient who had the clinical knowledge to seek out alternatives but recognized that most patients do not. The question she asks is not how to build a successful business in this space, though she is doing that. It is how to ensure that the patients who most need this technology are not the last ones to receive it.
That orientation has practical implications for how she builds. The choice of HawaiÊ»i as Pacific Biolúme’s founding territory is not simply a geographic convenience. It is a strategic decision rooted in the state’s cultural proximity to Asia, its diverse patient population, and its potential as a model for equitable technology introduction that can scale to other markets. The education-first approach of JCA Global is not a marketing strategy. It is a patient protection measure, ensuring that enthusiasm for a new technology does not outpace the understanding needed to use it safely and effectively.
A Vision That Extends Beyond the Market
Jaye Camposanto Andaya’s long-term ambitions make clear that her work is not primarily commercial, even as the commercial side of it grows.
She speaks about contributing to the policy conversations that will shape how regenerative medicine is regulated, understood, and distributed as the field matures. She envisions JCA Global Regenerative Advisory LLC becoming a recognized institutional voice in those conversations, one with the clinical credibility, cross-cultural expertise, and patient-centered orientation to represent the people most affected by how those decisions are made.
For a field that has too often prioritized investor returns over patient outcomes, that vision represents something genuinely different. It is the work of someone who arrived at this industry not as an entrepreneur looking for an opportunity, but as a patient looking for answers, and who decided, upon finding them, that the answers should be available to everyone.
That is, in the end, what patient advocacy looks like when it is built by someone who has been on both sides of the exam table.
